The Journal of Steroid Biochemistry and Molecular Biology
Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues
Introduction
There is substantial information that the human mammary cancer tissue contains the enzyme systems (aromatase, sulfatase, 17β-hydroxysteroid dehydrogenase) necessary for the last steps in the formation of estradiol (E2), the hormone that plays an important role in the origin and evolution of this disease [1], [2], [3]. Estrogens in this carcinoma tissue can originate through two main pathways, one from aromatase, which converts androgens to estrogens [4], [5], [6] and the other from sulfatase, which converts estrone sulfate into estrone (E1) [7], [8], [9], [10], [11], [12]. Estrone is converted to the biologically active estradiol by the action of the 17β-hydroxysteroid dehydrogenase (Type I) [13], [14], [15], [16]. Quantitative determinations in breast cancer tissues indicate that the “estrone sulfatase pathway” is 40–500 times that of the “aromatase pathway” [17], [18]. The present study compares the concentrations of E1, E2, and their sulfates (E1S and E2S), as well as the aromatase and estrone sulfatase activities in (i) breast cancer tissue, (ii) the peripheral area of the tissue, and (iii) the area of the mammary gland considered as normal, in patients with breast cancer.
Section snippets
Chemicals
[6,7-3H]-Estrone sulfate (SA: 49.0 Ci/mmol), [7-3H]-testosterone (SA: 27.7 Ci/mmol, [6,7-3H]-estrone (SA: 41.9 Ci/mmol), [4-14C]-estrone (SA: 57.6 mCi/mmol), [4-14C]-estradiol (SA: 57.0 mCi/mmol), were obtained from New England Nuclear Division (Du Pont de Nemours, Les Ulis, France). Estrone sulfate ammonium salt and β-NADPH were purchased from Sigma–Aldrich Chimie (St Quentin, Fallavier, France). Estrone and estradiol were obtained from Steraloids (Touzart et Matignon, Vitry-sur-Seine, France).
Estrogen concentrations in the different areas of the breast
Mammary tissues of post-menopausal patients with breast tumors were divided into three areas: tumoral, peripheral and normal tissue. Fig. 1 shows the levels of the most important free and conjugated estrogens: estrone (E1), estradiol (E2), estrone sulfate (E1S) and estradiol sulfate (E2S) in each of these three areas. It was observed that: (1) the concentrations of the four estrogens were higher in the tumoral tissue than in the peripheral tissue or the areas of the breast considered as normal;
Discussion
One of the important findings of the present data is the high concentration of various estrogens in the mammary gland of peri- and post-menopausal patients with breast cancer. This is of particular interest as during this period of life the ovary has ceased to produce these estrogens, suggesting that the hormone can be produced in the same organ where it exerts its biological response, which is also in agreement with the information that breast cancer tissue possesses all the enzymes necessary
Conclusion
The breast tumoral process is characterized by a modification of the estrogen metabolism, which corresponds to the establishment of two gradients: E1S and E2, and sulfatase and aromatase activities, when the tumoral and normal breast tissue are compared. These results indicate that therapeutical use of Selective Estrogen Enzyme Modulators (SEEM) can be an important additional treatment for breast cancer by reducing the rate of E2 in the tumor.
References (26)
- et al.
Steroid modulation of aromatase activity in human cultured breast carcinoma cells
J. Steroid Biochem
(1988) - et al.
Estrogen sulfatase and estrogen sulfotransferase in human primary mammary carcinoma
J. Steroid Biochem
(1983) - et al.
Biological effects and morphological responses to estriol, estriol-3-sulfate, estriol-17-sulfate and tamoxifen in a tamoxifen-resistant cell line (R-27) derived from MCF-7 human breast cancer cells
Eur. J. Cancer Clin. Oncol
(1986) - et al.
Importance of estrogen sulfates in breast cancer
J. Steroid Biochem
(1989) - et al.
Recent data on estrogen sulfatases and sulfotransferases activities in human breast cancer
J. Steroid Biochem. Molec. Biol
(1992) - et al.
Comparison of the in vitro conversion of estradiol-17β to estrone of normal and neoplastic human breast tissue
Molec. Cell. Endocr
(1977) Relationship between estrogen receptors, 17β-hydroxysteroid dehydrogenase and estrogen content in human breast cancer
Steroids
(1979)- et al.
Aromatase, 17β-hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women
Eur. J. Cancer Clin. Oncol
(1986) - et al.
Effect of Decapeptyl, an agonistic analog of gonadotropin-releasing hormone on estrogens, estrogen sulfates, and progesterone receptors in leiomyoma and myometrium
Fert. Steril
(1990) - et al.
Steroid metabolism by human breast and rat mammary carcinomata
Steroids
(1974)
Estrone sulfate and sulfatase activity in human breast cancer and endometrial cancer
J. Steroid Biochem
Metabolism of estrone sulfate by normal breast tissue: influence of menopausal status and oral contraceptives
J. Steroid Biochem. Molec. Biol
The role of hormones in the development of human breast cancer
Cited by (267)
A comprehensive review on novel delivery approaches for exemestane
2022, Journal of Drug Delivery Science and TechnologyIdentification of key structural features of phosphate and thiophosphate tricyclic coumarin analogs as STS inhibitors
2021, Medicine in Drug DiscoveryMechanisms of endocrine therapy resistance in breast cancer
2021, Molecular and Cellular Endocrinology17β-estradiol at low concentrations attenuates the efficacy of tamoxifen in breast cancer therapy
2019, Environmental PollutionCitation Excerpt :As an estrogen-dependent tumor, its initiation and progression are highly correlated with estrogen levels, although humans maintain a dynamic balance at different physiological stages (Nadal-Serrano et al., 2012; Rondon-Lagos et al., 2016). Moreover, constant low E2 concentrations are sufficient to increase breast cancer risk in premenopausal women though high levels of E2 are implicated in breast cancer in postmenopausal women (Chetrite et al., 2000; Rondon-Lagos et al., 2016). Other than endogenous estrogen, the unavoidable exposure of exogenous estrogen in the environment can aggravate carcinogenesis (Clemons and Goss, 2001).